Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

Abstract

Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Bortezomib has been shown to be highly active in MM patients with RI. We designed this retrospective analysis to investigate the safety and efficacy of bortezomib-based therapy in 117 MM patients with RI, 14 cases required dialysis. A total of 603 cycles of… (More)
DOI: 10.1111/j.1600-0609.2009.01385.x

Topics

Cite this paper

@article{Morabito2010SafetyAE, title={Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.}, author={F. Morabito and Massimo Gentile and Stefania Ciolli and Maria Teresa Petrucci and S Galimberti and Giuseppe Mele and Antonio Francesco Casulli and Donato Mannina and Eugenio Piro and Graziella Pinotti and Salvatore Palmieri and Lucio Catalano and Vincenzo Callea and Massimo Offidani and Pellegrino Musto and Sara Bringhen and Luca Baldini and Patrizia Tosi and Francesco Di Raimondo and Mario Boccadoro and Antonio Palumbo and Michele Cavo}, journal={European journal of haematology}, year={2010}, volume={84 3}, pages={223-8} }